Ulster University Logo

Incretin hormone mimetics and analogues in diabetes therapeutics

Green, Brian D. and Flatt, Peter (2007) Incretin hormone mimetics and analogues in diabetes therapeutics. BEST PRACTICE AND RESEARCH CLINICAL ENDOCRINOLOGY AND METABOLISM, 21 (4). pp. 497-516. [Journal article]

Full text not available from this repository.

DOI: 10.1016/i.beem.2007.09.003


The incretin hormones glucagon-like peptide-I (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are physiological gut peptides with insulin-releasing and extrapancreatic glucoregulatory actions. Incretin analogues/mimetics activate GLP-I or GIP receptors whilst avoiding physiological inactivation by dipeptidyl peptidase 4 (DPP-4), and they represent one of the newest classes of antidiabetic drug. The first clinically approved GLP-1 mimetic for the treatment of type-2 diabetes is exenatide (Byetta/exendin) which is administered subcutaneously twice daily. Clinical trials of liraglutide, a GLP-1 analogue suitable for once-daily administration, are ongoing. A number of other incretin molecules are at earlier stages of development. This review discusses the various attributes of GLP-1 and GIP for diabetes treatment and summarises current clinical data. Additionally, it explores the therapeutic possibilities offered by preclinical agents, such as non-peptide GLP-1 mimetics, GLP-1/glucagon hybrid peptides, and specific GIP receptor antagonists.

Item Type:Journal article
Faculties and Schools:Faculty of Life and Health Sciences
Faculty of Life and Health Sciences > School of Biomedical Sciences
Research Institutes and Groups:Biomedical Sciences Research Institute
Biomedical Sciences Research Institute > Diabetes
ID Code:2924
Deposited By: Professor Peter Flatt
Deposited On:17 Dec 2009 11:15
Last Modified:09 May 2016 10:48

Repository Staff Only: item control page